Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis

Acta Neurologica Scandinavica

Volumn 115, Issue 5, 2007, Pages 325-330

  Terzi, M ^a   Birinci, A ^a   Cetinkaya E ^a   Onar, M K ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Axonal damage; Multiple sclerosis; Tau

Indexed keywords

TAU PROTEIN;

ADULT; ARTICLE; AXONAL INJURY; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MULTIPLE SCLEROSIS; PROGNOSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TAU PROTEINS;

EID: 34247855864     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00782.x     Document Type: Article

References (31)

1. Miller AE. Clinical features. In : Cook SD, ed. Handbook of multiple sclerosis, 3rd edn. New York : Marcel Dekker, 2001 231 2.
2. Lassmann H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry 2003 74 : 695 7.
3. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005 4 : 32 41.
4. Zaffaroni M. Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol Sci 2003 24 : 279 82.
5. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997 120 : 393 9.
6. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002 59 : 1668 80.
7. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998 64 : 402 4.
8. Semra YK, Seide OA, Shairef MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002 122 : 132 9.
9. Martinez-Yelamos A, Saiz A, Sanchez R et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 2001 57 : 722 8.
10. Martinez-Yelamos A, Saiz A, Bas J et al. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 2004 363 : 14 7.
11. Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985 101 : 1371 8.
12. Arai H, Morikawa Y, Higuchi M et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997 236 : 262 4.
13. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50 : 121 7.
14. Carpenter AB. Enzyme-linked immunoassays. In : Rabin BS, ed. Manual of clinical laboratory immunology, 4th edn, 183-90. Washington, DC : American Society for Microbiology, 1992.
15. Eikelenboom MJ, Petzold A, Lazeron RHC et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003 60 : 219 23.
16. Izquierdo G, Angula S, Garcia-Moreno JM et al. Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand 2002 105 : 158 63.
17. Malmeström C, Haghighi S, Rosengren L et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003 61 : 1720 5.
18. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002 15 : 239 45.
19. Arai H, Terajima M, Higuchi S et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995 38 : 649 53.
20. Otto M, Wiltfang J, Tumani H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997 225 : 210 2.
21. Jimenez-Jimenez FJ, Zurdo JM, Hernanz A et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002 106 : 351 4.
22. Kapaki E, Paraskevas GP, Michalopoulou M, Klidiereas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000 43 : 228 32.
23. Brettschneider J, Maier M, Arda S et al. Tau protein in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005 11 : 261 5.
24. Trapp BD, Bö L, Mörk S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999 98 : 49 56.
25. Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001 300 : 95 8.
26. Guimaraes I, Cardoso MI, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006 12 : 354 6.
27. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995 59 : 280 3.
28. Parnetti L, Lanari A, Saggese E et al. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Neurol Sci 2003 24 : 199 200.
29. Blomberg M, Jensen M, Bsun H et al. CSF tau levels increase with age in healthy individuals. Dement Geriatr Cogn Disord 2001 12 : 127 32.
30. Sjögren M, Vanderstichele H, Agren H et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001 47 : 1776 81.
31. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004 251 : 414 20.